tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Enlivex Lists RAIN Treasury Token on KuCoin to Deepen Liquidity and Market Access

Story Highlights
  • Enlivex is a late-stage osteoarthritis biotech that also holds RAIN as its primary digital treasury reserve asset.
  • On January 6, 2026, Enlivex’s RAIN token was listed on major crypto exchange KuCoin, expanding global access and liquidity for its treasury holdings.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Enlivex Lists RAIN Treasury Token on KuCoin to Deepen Liquidity and Market Access

Claim 70% Off TipRanks Premium

Enlivex ( (ENLV) ) has shared an update.

On January 7, 2026, Enlivex Therapeutics announced that its primary digital treasury asset, the RAIN token, began trading on the KuCoin cryptocurrency exchange effective January 6, 2026, providing access to one of the world’s largest digital asset trading platforms and significantly broadening the token’s potential user base, particularly in Southeast Asia. By securing a listing on a major global venue known for deep retail liquidity, Enlivex aims to enhance market access and secondary liquidity for its RAIN holdings, marking a key milestone in its digital asset treasury strategy and underscoring the company’s dual positioning at the intersection of late-stage osteoarthritis drug development and emerging decentralized finance infrastructure.

The most recent analyst rating on (ENLV) stock is a Hold with a $0.72 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Spark’s Take on ENLV Stock

According to Spark, TipRanks’ AI Analyst, ENLV is a Neutral.

The score is primarily weighed down by weak financial performance typical of a pre-revenue biotech (ongoing losses and negative free cash flow), alongside bearish technicals with the price below major moving averages and negative MACD. Valuation contributes little support due to a negative P/E and no dividend.

To see Spark’s full report on ENLV stock, click here.

More about Enlivex

Enlivex Therapeutics Ltd., based in Nes-Ziona, Israel, is a publicly listed biotech company focused on the late-stage clinical development of Allocetra™, a novel therapy targeting osteoarthritis, a highly prevalent and disabling joint disease with significant unmet medical need. In parallel, Enlivex has adopted a digital asset treasury strategy centered on the RAIN token, positioning itself as the first public company to use RAIN as its primary treasury reserve asset and to offer investors indirect exposure to this governance and utility token for a decentralized predictions and options protocol on the Arbitrum network.

Average Trading Volume: 3,912,750

Technical Sentiment Signal: Sell

Current Market Cap: $185.5M

For detailed information about ENLV stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1